An economic model to reduce the cost of chemotherapy for gynecologic cancer

International Journal of Fertility and Women's Medicine

Volumn 49, Issue 6, 2004, Pages 274-277

  Jacobs, Volker R ^a   Thoedtmann, Jutta ^a   Brunner, Bettina ^a   Kiechle, Marion ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Chemotherapy; Cost effectiveness; Oncology; Pharmaco economics

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMICS; FEMALE; FEMALE GENITAL TRACT TUMOR; GERMANY; HUMAN; REIMBURSEMENT; STATISTICAL MODEL; STATISTICS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GENITAL NEOPLASMS, FEMALE; GERMANY; HUMANS; MODELS, ECONOMIC; REIMBURSEMENT MECHANISMS;

EID: 14944365537     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Gieseking F, Leppek K, Ramthun B, et al: Finanzierbarkeit gynäkologisch/onkologischer Therapien. [Affordability of gynaecologic/oncologic therapies.] Gynakologe 33(7):508-513, 2000.
2. Jacobs VR, Thödtmann J, Brunner B, et al: Ein "Case-by-Case- Management" gynäko-onkologischer Therapien zur Reduktion von Medikamentenkosten um 58,7% innerhalb eines Jahres. [A "Case-by-Case- Management" of gyneco-oncologic therapies for reduction of drug costs of 58.5% within one year.] 11th German Hospital-Controller-Day, Munich, Germany, April 29-30, 2004.